Company / Capital Expenditures
Arcus Biosciences, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$2.0M
FY2025
5-year range
$2.0M / $26.0M
FY2021-FY2025
Trend
-66.7%
vs FY2024
Sector context
#95 of 194
Health Care
What the data says
At $2M, Arcus Biosciences, Inc.'s capital expenditures ranks #95 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $2M in FY2019 to $26M in FY2021.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -11.8%.
Declined from $24M to $2M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -12.6%
- 5-Year CAGR
- -11.8%
- 10-Year CAGR
- -
Sector benchmark
#95 of 194 in Health CareTop 49% of 194This company $2.0M Sector average $117.5M
▼
-98.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -11.8%, indicating a declining trend.
- In FY2025, capital expenditures decreased 66.7% year-over-year.
- Ranks #95 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -0.93 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0M | -66.7% |
| FY2024 | $6.0M | -75.0% |
| FY2023 | $24.0M | +700.0% |
| FY2022 | $3.0M | -88.5% |
| FY2021 | $26.0M | +594.6% |
| FY2020 | $3.7M | +94.4% |
| FY2019 | $1.9M | -53.0% |
| FY2018 | $4.1M | -25.7% |
| FY2017 | $5.5M | +34.5% |
| FY2016 | $4.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026